Shares of Oculis Holding AG (NASDAQ:OCS - Get Free Report) saw unusually-high trading volume on Wednesday . Approximately 70,058 shares were traded during mid-day trading, a decline of 38% from the previous session's volume of 112,347 shares.The stock last traded at $18.55 and had previously closed at $18.22.
Analyst Ratings Changes
Several research firms recently commented on OCS. HC Wainwright reiterated a "buy" rating and issued a $30.00 price objective on shares of Oculis in a report on Monday. Chardan Capital reiterated a "buy" rating and issued a $28.00 price target on shares of Oculis in a research note on Tuesday. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $28.80.
Get Our Latest Stock Report on Oculis
Oculis Stock Performance
The business has a fifty day simple moving average of $16.35 and a two-hundred day simple moving average of $13.84. The company has a market cap of $757.42 million, a P/E ratio of -9.69 and a beta of -0.33. The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.01.
About Oculis
(
Get Free Report)
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Recommended Stories
Before you consider Oculis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oculis wasn't on the list.
While Oculis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
